3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
17
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Prostate Adenocarcinoma
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Metastatic Castration-sensitive Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Bevacizumab
112
Fluorouracil
98
Oxaliplatin
96
Leucovorin
96
Irinotecan
86
Capecitabine
73
Cetuximab
64
Panitumumab
42
pembrolizumab
38
regorafenib
28
Nivolumab
23
IFL protocol
22
Folfox protocol
21
trifluridine tipiracil drug combination
14
Radiotherapy
13
durvalumab
11
Gemcitabine
10
Celecoxib
10
tremelimumab
7
binimetinib
7
aflibercept
7
Drug Therapy
7
Disulfides
7
Cyclophosphamide
7
Trifluridine
6
Trastuzumab
6
Sunitinib
6
Paclitaxel
6
Immunoglobulin G
6
Colonoscopy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colorectal Neoplasms
×
niraparib
×
Clear all
NCT03983993
2026-01-05
NIPAVect
Emory University
Phase 2
Active not recruiting
26 enrolled
8 charts